0001213900-14-000064.txt : 20140107 0001213900-14-000064.hdr.sgml : 20140107 20140107160451 ACCESSION NUMBER: 0001213900-14-000064 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20140107 DATE AS OF CHANGE: 20140107 EFFECTIVENESS DATE: 20140107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Actinium Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001388320 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 880378336 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-209458 FILM NUMBER: 14513489 BUSINESS ADDRESS: STREET 1: 501 FIFTH AVENUE, 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-300-2131 MAIL ADDRESS: STREET 1: 501 FIFTH AVENUE, 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: Cactus Ventures, Inc. DATE OF NAME CHANGE: 20070130 D 1 primary_doc.xml X0707 D LIVE 0001388320 Actinium Pharmaceuticals, Inc. 501 FIFTH AVENUE 3RD FLOOR NEW YORK NY NEW YORK 10017 (646)459-4201 DELAWARE None Cactus Ventures, Inc. Corporation true Kaushik J. Dave 501 Fifth Avenue 3rd Floor New York NY NEW YORK 10017 Executive Officer Director President and Chief Executive Officer Sergio Traversa 501 Fifth Avenue 3rd Floor New York NY NEW YORK 10017 Executive Officer Director Interim Chief Financial Officer Dragan Cicic 501 Fifth Avenue 3rd Floor New York NY NEW YORK 10017 Executive Officer Chief Operating Officer and Chief Medical Officer David Nicholson 501 Fifth Avenue 3rd Floor New York NY NEW YORK 10017 Director Sandesh Seth 501 Fifth Avenue 3rd Floor New York NY NEW YORK 10017 Director Chairman of the Board Richard I. Steinhart 501 Fifth Avenue 3rd Floor New York NY NEW YORK 10017 Director Pharmaceuticals No Revenues 06b false 2013-12-27 false true true false 5000 Recipient Laidlaw & Company (UK) Ltd. 119037 None None 546 FIFTH AVENUE, 5TH FLOOR NEW YORK NY NEW YORK 10036 CA CALIFORNIA CO COLORADO FL FLORIDA GA GEORGIA MA MASSACHUSETTS NY NEW YORK OR OREGON TX TEXAS WV WEST VIRGINIA false 6000000 3325860 2674140 This offering also has a $2,000,000 overallotment that can be sold if there is sufficient demand. false 36 332586 0 Included in the sales commission amount is a 2% allowance for expenses paid to the agent. The agent also received warrants to purchase 69,289 shares of common stock of the issuer. 0 In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors. false Actinium Pharmaceuticals, Inc. /s/ Kaushik J. Dave Kaushik J. Dave President and Chief Executive Officer 2014-01-07